Rare condition
Enthesitis-related juvenile idiopathic arthritis
5
studies recruiting now
as of 7 Sept 2026
20
studies registered in total
as of 7 Sept 2026
23
countries with a recruiting site
as of 7 Sept 2026
31 Oct 2024
most recent study posted
among recruiting studies
Recruiting trials
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Enthesitis-related juvenile idiopathic arthritis studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Enthesitis-related juvenile idiopathic arthritis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Enthesitis-related juvenile idiopathic arthritis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).